Tuesday, September 29, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Compoundingsemaglutidetirzepatidemochi healthtelehealth

Mochi Health cuts compounded semaglutide price to $60 a month

The telehealth platform tied pricing to dose level and added an in-platform bloodwork service, Mochi Labs, in most states.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 29 07:32 ETSource: usatoday.com

The wire

  1. 01Mochi Health moved to dose-based pricing, with compounded semaglutide starting at $60 per month and compounded tirzepatide at $90, plus memberships from $39 for the first month.
  2. 02Dose-tiered pricing undercuts entry costs for new patients and signals continued price competition among telehealth sellers of compounded incretins.
  3. 03Compounded semaglutide and tirzepatide are not FDA-approved; Mochi Labs is unavailable in New York, New Jersey, Rhode Island and Hawaii, and the pricing claims are the company's own.

From the source

A popular GLP-1 provider just made its weight loss medications cheaper

Mochi Health just lowered the cost of its compounded GLP-1 medications while adding a new lab-testing service designed to help patients track key health markers during treatment.

Read at usatoday.com
PeptiPrescribed peptides from $99/moSee all →